glp 1 and afib Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis HRS 2026: GLP-1 Receptor Agonists
Description
Zinman B, Bhosekar V, Busch R, et al
By regulating appetite and energy balance, GLP-1 therapies also support healthier circadian rhythms, enabling patients to achieve more restorative sleep
To access deeper insights on emerging innovations, consumer shifts, and market opportunities in the GLP-1 space, download our full report today
Additional insights come from the phase 3 STEP trial (STEP 3), which combined 2.4 mg semaglutide with an intensive low-calorie diet (10001200 kcal/day meal replacements for the first 8 weeks, followed by a hypocaloric diet of 12001800 kcal/day) and progressive increases in physical activity to 200 minutes per week [13]
The analysis utilized data from the LEADER and SUSTAIN 6 cardiovascular outcome trials
